Raymond James Trust’s Novartis NVS Stock Holding History

Raymond James Trust’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$1.77M	Buy	15,384 +963	+7%	+$109K	0.04%	349
2024 Q2	$1.54M	Buy	14,421 +653	+5%	+$65.5K	0.04%	365
2024 Q1	$1.33M	Sell	13,768 -39	-0.3%	-$4K	0.03%	399
2023 Q4	$1.39M	Sell	13,807 -349	-2%	-$33.7K	0.04%	373
2023 Q3	$1.44M	Sell	14,156 -69	-0.5%	-$7K	0.04%	335
2023 Q2	$1.44M	Sell	14,225 -861	-6%	-$86.1K	0.04%	337
2023 Q1	$1.39M	Sell	15,086 -1,318	-8%	-$115K	0.04%	336
2022 Q4	$1.49M	Sell	16,404 -186	-1%	-$15.7K	0.05%	304
2022 Q3	$1.26M	Sell	16,590 -587	-3%	-$48.7K	0.05%	322
2022 Q2	$1.45M	Sell	17,177 -2,922	-15%	-$256K	0.05%	300
2022 Q1	$1.76M	Buy	20,099 +901	+5%	+$78K	0.05%	281
2021 Q4	$1.68M	Sell	19,198 -668	-3%	-$55.5K	0.05%	301
2021 Q3	$1.63M	Sell	19,866 -828	-4%	-$74.5K	0.05%	284
2021 Q2	$1.89M	Sell	20,694 -9,276	-31%	-$826K	0.06%	262
2021 Q1	$2.56M	Sell	29,970 -8,026	-21%	-$720K	0.09%	199
2020 Q4	$3.59M	Sell	37,996 -135	-0.4%	-$11.8K	0.14%	139
2020 Q3	$3.32M	Sell	38,131 -2,595	-6%	-$225K	0.14%	132
2020 Q2	$3.56M	Buy	40,726 +4,404	+12%	+$380K	0.17%	122
2020 Q1	$3M	Sell	36,322 -2,177	-6%	-$194K	0.18%	124
2019 Q4	$3.65M	Buy	38,499 +129	+0.3%	+$11.6K	0.17%	125
2019 Q3	$3.33M	Sell	38,370 -15,649	-29%	-$1.41M	0.17%	125
2019 Q2	$4.93M	Sell	54,019 -967	-2%	-$81.8K	0.27%	89
2019 Q1	$4.74M	Buy	54,986 +1,995	+4%	+$160K	0.27%	90
2018 Q4	$4.08M	Buy	52,991 +237	+0.4%	+$18.4K	0.26%	94
2018 Q3	$4.07M	Buy	52,754 +15,554	+42%	+$1.15M	0.23%	98
2018 Q2	$2.52M	Buy	37,200 +3,118	+9%	+$215K	0.15%	144
2018 Q1	$2.47M	Sell	34,082 -177	-0.5%	-$13.5K	0.17%	132
2017 Q4	$2.58M	Sell	34,259 -1,214	-3%	-$91.6K	0.17%	127
2017 Q3	$2.73M	Buy	35,473 +108	+0.3%	+$8.16K	0.2%	119
2017 Q2	$2.65M	Sell	35,365 -11,468	-24%	-$813K	0.2%	119
2017 Q1	$3.12M	Buy	46,833 +1,464	+3%	+$97.6K	0.24%	103
2016 Q4	$2.96M	Buy	45,369 +11,160	+33%	+$724K	0.24%	105
2016 Q3	$2.42M	Buy	34,209 +3,715	+12%	+$271K	0.21%	112
2016 Q2	$2.25M	Sell	30,494 -168	-0.5%	-$11.6K	0.2%	115
2016 Q1	$1.99M	Sell	30,662 -1,129	-4%	-$76.8K	0.19%	122
2015 Q4	$2.45M	Buy	31,791 +4,977	+19%	+$395K	0.23%	102
2015 Q3	$2.21M	Buy	26,814 +375	+1%	+$33.4K	0.25%	97
2015 Q2	$2.33M	Sell	26,439 -2,321	-8%	-$213K	0.25%	97
2015 Q1	$2.54M	Buy	28,760 +706	+3%	+$62.6K	0.27%	89
2014 Q4	$2.33M	Buy	28,054 +461	+2%	+$38.2K	0.25%	93
2014 Q3	$2.33M	Buy	27,593 +1,599	+6%	+$129K	0.27%	90
2014 Q2	$2.11M	Buy	25,994 +423	+2%	+$33.3K	0.24%	97
2014 Q1	$1.95M	Buy	25,571 +1,510	+6%	+$110K	0.24%	98
2013 Q4	$1.73M	Sell	24,061 -706	-3%	-$49.1K	0.23%	107
2013 Q3	$1.7M	Buy	24,767 +473	+2%	+$31.3K	0.26%	98
2013 Q2	$1.54M	Buy	+24,294	New	+$1.58M	0.25%	102

Other funds holding NVS

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Raymond James Trust's NVS Position: Q3 2024 in Review

Raymond James Trust increased its Novartis (NVS) stake by 6.7% in Q3 2024, buying an estimated $109K and bringing the position to 15,384 shares worth $1.77M. The position accounts for 0.04% of the portfolio, ranked #349.

Raymond James Trust first reported a position in NVS in Q2 2013 and has held it in 46 quarters since. The position peaked at $4.93M in Q2 2019. 1,311 funds tracked by Wall St. Rank hold NVS as of Q3 2024.

Raymond James Trust held 15,384 shares of Novartis worth $1.77M as of Q3 2024.
Raymond James Trust bought 963 Novartis shares in Q3 2024, an estimated $109K.
Novartis made up 0.04% of Raymond James Trust's portfolio in Q3 2024, its #349 holding.
Raymond James Trust first reported a position in Novartis in Q2 2013 and has held it in 46 quarters since.
Raymond James Trust's Novartis position peaked at $4.93M in Q2 2019.
1,311 funds tracked by Wall St. Rank held Novartis as of Q3 2024.

Based on Raymond James Trust's 13F filing for Q3 2024, filed 12 Nov 2024.